Off-the-shelf natural killer cell therapy company, targeting solid and hematological cancers Raises US$8M from US-based investor Acorn Bioventures and current shareholders, bringing total raised in last six months to US$14.6M Funding will enable expansion of R&D and manufacturing capabilities, and progression of its two lead programs towards the clinic: ONKT101 a dual-targeted NK cell therapy […]